Douglas Seals
Concepts (780)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 202 | 2026 | 1973 | 20.340 |
Why?
| | Endothelium, Vascular | 88 | 2026 | 956 | 14.850 |
Why?
| | Vascular Stiffness | 48 | 2026 | 487 | 9.490 |
Why?
| | Oxidative Stress | 70 | 2026 | 1360 | 8.330 |
Why?
| | Exercise | 104 | 2026 | 2205 | 8.060 |
Why?
| | Vasodilation | 63 | 2025 | 521 | 7.820 |
Why?
| | Arteries | 33 | 2024 | 261 | 6.270 |
Why?
| | Sympathetic Nervous System | 69 | 2026 | 181 | 6.180 |
Why?
| | Brachial Artery | 40 | 2025 | 208 | 6.080 |
Why?
| | Blood Pressure | 106 | 2026 | 1782 | 5.900 |
Why?
| | Biomedical Research | 12 | 2024 | 719 | 4.660 |
Why?
| | Writing | 8 | 2024 | 101 | 4.420 |
Why?
| | Carotid Arteries | 29 | 2025 | 208 | 4.150 |
Why?
| | Aorta | 21 | 2026 | 440 | 4.060 |
Why?
| | Physical Endurance | 49 | 2026 | 279 | 3.730 |
Why?
| | Vascular Diseases | 15 | 2023 | 252 | 3.520 |
Why?
| | Antioxidants | 25 | 2026 | 550 | 3.410 |
Why?
| | Nitric Oxide | 34 | 2025 | 892 | 3.260 |
Why?
| | Cardiovascular Diseases | 30 | 2026 | 2191 | 3.120 |
Why?
| | Regional Blood Flow | 36 | 2020 | 514 | 3.100 |
Why?
| | Physiology | 5 | 2024 | 13 | 2.950 |
Why?
| | Publishing | 5 | 2023 | 114 | 2.890 |
Why?
| | Sodium Nitrite | 8 | 2021 | 39 | 2.860 |
Why?
| | Heart Rate | 84 | 2023 | 856 | 2.820 |
Why?
| | Postmenopause | 28 | 2026 | 394 | 2.800 |
Why?
| | Endothelial Cells | 24 | 2026 | 878 | 2.740 |
Why?
| | Resistance Training | 5 | 2023 | 186 | 2.570 |
Why?
| | Mitochondria | 12 | 2026 | 993 | 2.540 |
Why?
| | Hypertension | 24 | 2025 | 1276 | 2.490 |
Why?
| | Aged | 182 | 2026 | 26217 | 2.480 |
Why?
| | Dietary Supplements | 21 | 2026 | 584 | 2.360 |
Why?
| | Blood Vessels | 6 | 2020 | 167 | 2.280 |
Why?
| | Pulse Wave Analysis | 25 | 2026 | 267 | 2.250 |
Why?
| | Caloric Restriction | 10 | 2021 | 133 | 2.240 |
Why?
| | Middle Aged | 205 | 2026 | 36309 | 2.220 |
Why?
| | Physical Exertion | 34 | 2014 | 205 | 2.150 |
Why?
| | Exercise Tolerance | 10 | 2026 | 283 | 2.140 |
Why?
| | Cellular Senescence | 12 | 2026 | 226 | 2.130 |
Why?
| | Diet, Sodium-Restricted | 8 | 2020 | 38 | 2.090 |
Why?
| | Cardiovascular Physiological Phenomena | 14 | 2026 | 49 | 2.020 |
Why?
| | Oxygen Consumption | 48 | 2026 | 719 | 2.010 |
Why?
| | Humans | 360 | 2026 | 145783 | 2.010 |
Why?
| | Male | 268 | 2026 | 73010 | 1.980 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 203 | 1.950 |
Why?
| | Inflammation | 24 | 2024 | 2884 | 1.930 |
Why?
| | Muscles | 32 | 2023 | 330 | 1.910 |
Why?
| | Physical Fitness | 20 | 2013 | 207 | 1.910 |
Why?
| | Ascorbic Acid | 17 | 2025 | 184 | 1.890 |
Why?
| | Baroreflex | 16 | 2016 | 57 | 1.880 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 242 | 1.850 |
Why?
| | Methylamines | 6 | 2022 | 39 | 1.810 |
Why?
| | NF-kappa B | 9 | 2015 | 667 | 1.800 |
Why?
| | Superoxides | 16 | 2022 | 198 | 1.750 |
Why?
| | Peer Review | 4 | 2023 | 47 | 1.750 |
Why?
| | Vasodilator Agents | 12 | 2024 | 330 | 1.710 |
Why?
| | Acetylcholine | 12 | 2023 | 209 | 1.610 |
Why?
| | Mice | 60 | 2026 | 18355 | 1.560 |
Why?
| | Animals | 91 | 2026 | 38101 | 1.540 |
Why?
| | Norepinephrine | 29 | 2011 | 201 | 1.510 |
Why?
| | Female | 187 | 2026 | 79045 | 1.460 |
Why?
| | Adult | 204 | 2026 | 40881 | 1.450 |
Why?
| | Diet, Western | 3 | 2022 | 88 | 1.450 |
Why?
| | Heart | 16 | 2018 | 626 | 1.430 |
Why?
| | Cardiovascular System | 11 | 2026 | 139 | 1.430 |
Why?
| | Mice, Inbred C57BL | 33 | 2026 | 5992 | 1.400 |
Why?
| | Adipose Tissue | 19 | 2018 | 645 | 1.380 |
Why?
| | Healthy Aging | 4 | 2024 | 44 | 1.370 |
Why?
| | Doxorubicin | 6 | 2026 | 403 | 1.370 |
Why?
| | Vascular Resistance | 20 | 2012 | 370 | 1.340 |
Why?
| | Motor Activity | 8 | 2024 | 718 | 1.300 |
Why?
| | Salicylates | 5 | 2015 | 29 | 1.270 |
Why?
| | Respiratory Muscles | 5 | 2023 | 37 | 1.270 |
Why?
| | Forearm | 18 | 2023 | 141 | 1.260 |
Why?
| | NADPH Oxidases | 13 | 2020 | 122 | 1.240 |
Why?
| | Autonomic Nervous System | 11 | 2008 | 83 | 1.170 |
Why?
| | Research Personnel | 4 | 2023 | 185 | 1.160 |
Why?
| | Muscle, Skeletal | 24 | 2026 | 1791 | 1.140 |
Why?
| | Age Factors | 29 | 2025 | 3346 | 1.140 |
Why?
| | Reactive Oxygen Species | 14 | 2025 | 611 | 1.130 |
Why?
| | Estrogens | 8 | 2023 | 367 | 1.120 |
Why?
| | Double-Blind Method | 17 | 2025 | 2064 | 1.110 |
Why?
| | Tyrosine | 14 | 2020 | 217 | 1.090 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 37 | 1.070 |
Why?
| | Vasoconstriction | 7 | 2017 | 216 | 1.070 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 286 | 1.020 |
Why?
| | Femoral Artery | 11 | 2013 | 190 | 1.010 |
Why?
| | NAD | 5 | 2023 | 79 | 1.000 |
Why?
| | Geriatrics | 4 | 2015 | 95 | 0.980 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 0.980 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 0.980 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 143 | 0.970 |
Why?
| | Inflammation Mediators | 6 | 2025 | 507 | 0.950 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 346 | 0.950 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 58 | 0.930 |
Why?
| | Flavonols | 4 | 2026 | 27 | 0.880 |
Why?
| | Longevity | 4 | 2015 | 178 | 0.880 |
Why?
| | Metabolomics | 4 | 2021 | 733 | 0.870 |
Why?
| | Cross-Over Studies | 11 | 2026 | 610 | 0.870 |
Why?
| | Interleukin-1 | 5 | 2022 | 961 | 0.860 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 32 | 0.860 |
Why?
| | Elasticity | 11 | 2017 | 189 | 0.850 |
Why?
| | Running | 17 | 2026 | 233 | 0.850 |
Why?
| | Bottle-Nosed Dolphin | 1 | 2024 | 3 | 0.850 |
Why?
| | Curcumin | 2 | 2017 | 29 | 0.850 |
Why?
| | Drinking Water | 2 | 2022 | 90 | 0.830 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.820 |
Why?
| | Habits | 7 | 2017 | 52 | 0.820 |
Why?
| | Women's Health | 1 | 2026 | 316 | 0.800 |
Why?
| | Trehalose | 4 | 2017 | 35 | 0.790 |
Why?
| | Career Choice | 2 | 2024 | 235 | 0.790 |
Why?
| | Niacinamide | 4 | 2025 | 104 | 0.790 |
Why?
| | Body Composition | 30 | 2012 | 693 | 0.780 |
Why?
| | Cardiorespiratory Fitness | 3 | 2025 | 74 | 0.780 |
Why?
| | Financing, Organized | 1 | 2023 | 36 | 0.780 |
Why?
| | Physical Education and Training | 15 | 2024 | 70 | 0.780 |
Why?
| | Peer Review, Research | 1 | 2023 | 36 | 0.770 |
Why?
| | Compliance | 15 | 2017 | 50 | 0.770 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 768 | 0.770 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 105 | 0.770 |
Why?
| | Research Support as Topic | 1 | 2023 | 81 | 0.770 |
Why?
| | Fenofibrate | 2 | 2013 | 28 | 0.760 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 104 | 0.760 |
Why?
| | Elastin | 6 | 2023 | 78 | 0.740 |
Why?
| | Goals | 1 | 2024 | 185 | 0.740 |
Why?
| | Dementia | 2 | 2025 | 328 | 0.740 |
Why?
| | Vaping | 1 | 2023 | 74 | 0.730 |
Why?
| | Glycation End Products, Advanced | 4 | 2025 | 81 | 0.730 |
Why?
| | Lyases | 1 | 2022 | 15 | 0.730 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 9 | 0.730 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 89 | 0.720 |
Why?
| | Sodium, Dietary | 4 | 2013 | 42 | 0.720 |
Why?
| | Young Adult | 29 | 2025 | 14254 | 0.720 |
Why?
| | Transcriptome | 3 | 2023 | 1042 | 0.720 |
Why?
| | Muscle Strength | 6 | 2023 | 332 | 0.720 |
Why?
| | Renal Insufficiency, Chronic | 7 | 2025 | 668 | 0.720 |
Why?
| | Research Design | 4 | 2022 | 1139 | 0.710 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 110 | 0.710 |
Why?
| | Rest | 13 | 2007 | 126 | 0.710 |
Why?
| | Stress, Physiological | 12 | 2017 | 443 | 0.700 |
Why?
| | Speech | 1 | 2022 | 76 | 0.700 |
Why?
| | Hemodynamics | 17 | 2023 | 1118 | 0.690 |
Why?
| | Aortitis | 2 | 2011 | 10 | 0.690 |
Why?
| | Obesity | 14 | 2023 | 3118 | 0.690 |
Why?
| | Vagus Nerve | 7 | 2005 | 92 | 0.690 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.680 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.680 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.680 |
Why?
| | Leg | 14 | 2007 | 242 | 0.670 |
Why?
| | Flavonoids | 3 | 2026 | 85 | 0.670 |
Why?
| | Models, Animal | 6 | 2024 | 392 | 0.670 |
Why?
| | Spin Labels | 8 | 2020 | 59 | 0.670 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1217 | 0.660 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 308 | 0.660 |
Why?
| | Autophagy | 3 | 2017 | 291 | 0.650 |
Why?
| | Reference Values | 26 | 2021 | 798 | 0.650 |
Why?
| | Ubiquinone | 2 | 2026 | 35 | 0.640 |
Why?
| | Isometric Contraction | 14 | 1996 | 190 | 0.640 |
Why?
| | Comprehension | 1 | 2022 | 187 | 0.630 |
Why?
| | Cytokines | 10 | 2019 | 2069 | 0.630 |
Why?
| | Cardiac Output | 15 | 2004 | 179 | 0.630 |
Why?
| | Life Style | 14 | 2017 | 486 | 0.630 |
Why?
| | Biomarkers | 19 | 2025 | 4302 | 0.630 |
Why?
| | Fasting | 2 | 2020 | 279 | 0.620 |
Why?
| | Nitroglycerin | 3 | 2020 | 14 | 0.610 |
Why?
| | Frailty | 2 | 2024 | 205 | 0.610 |
Why?
| | Exercise Therapy | 9 | 2025 | 475 | 0.610 |
Why?
| | Organophosphorus Compounds | 2 | 2026 | 84 | 0.600 |
Why?
| | Spermidine | 2 | 2024 | 18 | 0.590 |
Why?
| | Nitrites | 3 | 2014 | 88 | 0.590 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 38 | 0.580 |
Why?
| | Isoproterenol | 4 | 2007 | 96 | 0.570 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 92 | 0.570 |
Why?
| | Overweight | 3 | 2009 | 614 | 0.560 |
Why?
| | Sirtuin 1 | 3 | 2016 | 34 | 0.560 |
Why?
| | Mentoring | 1 | 2021 | 166 | 0.560 |
Why?
| | Energy Metabolism | 9 | 2007 | 935 | 0.560 |
Why?
| | Sex Characteristics | 13 | 2011 | 789 | 0.550 |
Why?
| | Adolescent | 46 | 2023 | 22577 | 0.550 |
Why?
| | Lipids | 6 | 2018 | 707 | 0.550 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 560 | 0.550 |
Why?
| | Amino Acids | 2 | 2019 | 519 | 0.530 |
Why?
| | Health Status | 3 | 2019 | 835 | 0.530 |
Why?
| | Body Constitution | 4 | 2005 | 51 | 0.530 |
Why?
| | Blood Volume | 8 | 1998 | 65 | 0.530 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 119 | 0.530 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 31 | 0.530 |
Why?
| | Tunica Intima | 7 | 2006 | 78 | 0.510 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 450 | 0.510 |
Why?
| | Diet | 6 | 2024 | 1278 | 0.510 |
Why?
| | Nitroprusside | 5 | 2011 | 71 | 0.510 |
Why?
| | Epinephrine | 14 | 2007 | 158 | 0.500 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2181 | 0.490 |
Why?
| | Serine | 2 | 2015 | 143 | 0.490 |
Why?
| | Extracellular Matrix | 1 | 2021 | 563 | 0.490 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 86 | 0.480 |
Why?
| | Basal Metabolism | 4 | 2004 | 59 | 0.480 |
Why?
| | Muscle Contraction | 13 | 2003 | 429 | 0.480 |
Why?
| | Diet Therapy | 1 | 2016 | 36 | 0.480 |
Why?
| | Athletes | 3 | 2026 | 425 | 0.480 |
Why?
| | Glucose | 4 | 2019 | 1049 | 0.480 |
Why?
| | Hand Strength | 5 | 2026 | 144 | 0.480 |
Why?
| | Time Factors | 21 | 2021 | 7134 | 0.460 |
Why?
| | Primary Prevention | 1 | 2018 | 222 | 0.460 |
Why?
| | Cognition | 3 | 2025 | 1271 | 0.460 |
Why?
| | Estradiol | 3 | 2021 | 515 | 0.460 |
Why?
| | Premenopause | 9 | 2025 | 125 | 0.450 |
Why?
| | Aniline Compounds | 3 | 2025 | 120 | 0.450 |
Why?
| | Cross-Sectional Studies | 23 | 2025 | 5925 | 0.450 |
Why?
| | Colorado | 7 | 2026 | 4556 | 0.440 |
Why?
| | Risk Factors | 20 | 2025 | 10919 | 0.440 |
Why?
| | Blood Glucose | 10 | 2017 | 2344 | 0.430 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 23 | 0.430 |
Why?
| | Reflex | 6 | 2001 | 70 | 0.430 |
Why?
| | Collagen | 3 | 2021 | 457 | 0.420 |
Why?
| | Body Mass Index | 18 | 2015 | 2447 | 0.420 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2025 | 140 | 0.420 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 192 | 0.420 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.410 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 468 | 0.400 |
Why?
| | Niacin | 1 | 2013 | 16 | 0.400 |
Why?
| | Atherosclerosis | 1 | 2018 | 409 | 0.400 |
Why?
| | Geriatric Assessment | 2 | 2015 | 240 | 0.400 |
Why?
| | Nitrates | 4 | 2022 | 96 | 0.400 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.400 |
Why?
| | Proteome | 1 | 2018 | 513 | 0.400 |
Why?
| | Vitamin B Complex | 1 | 2013 | 39 | 0.390 |
Why?
| | Hindlimb | 1 | 2014 | 132 | 0.390 |
Why?
| | Eating | 2 | 2007 | 387 | 0.380 |
Why?
| | Locomotion | 1 | 2014 | 101 | 0.380 |
Why?
| | Aortic Diseases | 1 | 2014 | 125 | 0.380 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 217 | 0.380 |
Why?
| | Exercise Test | 12 | 2021 | 630 | 0.370 |
Why?
| | Arm | 7 | 2008 | 110 | 0.370 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 19 | 0.370 |
Why?
| | Ganglionic Blockers | 7 | 2008 | 9 | 0.370 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 2024 | 117 | 0.360 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 70 | 0.360 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 47 | 0.360 |
Why?
| | Allopurinol | 2 | 2016 | 70 | 0.350 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 2028 | 0.350 |
Why?
| | Pressoreceptors | 6 | 2001 | 19 | 0.350 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 75 | 0.340 |
Why?
| | Arteritis | 1 | 2011 | 23 | 0.340 |
Why?
| | Adrenal Glands | 3 | 2000 | 76 | 0.330 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 143 | 0.330 |
Why?
| | C-Reactive Protein | 3 | 2022 | 423 | 0.330 |
Why?
| | Oxidants | 1 | 2011 | 99 | 0.330 |
Why?
| | Postural Balance | 1 | 2014 | 247 | 0.330 |
Why?
| | Ultrasonography | 11 | 2017 | 788 | 0.330 |
Why?
| | Systole | 6 | 2020 | 181 | 0.320 |
Why?
| | Uric Acid | 1 | 2012 | 167 | 0.320 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 360 | 0.320 |
Why?
| | Behavior, Animal | 1 | 2014 | 520 | 0.320 |
Why?
| | Athletic Performance | 2 | 2012 | 78 | 0.310 |
Why?
| | Pilot Projects | 5 | 2025 | 1898 | 0.310 |
Why?
| | Analysis of Variance | 7 | 2011 | 1300 | 0.310 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 209 | 0.300 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 177 | 0.300 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2219 | 0.300 |
Why?
| | Peroxidase | 1 | 2010 | 168 | 0.290 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 36 | 0.290 |
Why?
| | Metabolome | 3 | 2018 | 391 | 0.290 |
Why?
| | Interleukins | 2 | 2022 | 248 | 0.290 |
Why?
| | Hot Temperature | 5 | 1993 | 396 | 0.290 |
Why?
| | Extremities | 2 | 2001 | 142 | 0.290 |
Why?
| | Blood Circulation | 4 | 2021 | 44 | 0.290 |
Why?
| | Biological Availability | 4 | 2021 | 145 | 0.290 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 190 | 0.280 |
Why?
| | Interleukin-6 | 4 | 2024 | 780 | 0.280 |
Why?
| | Vitamin D | 2 | 2017 | 404 | 0.280 |
Why?
| | Cells, Cultured | 5 | 2025 | 4151 | 0.280 |
Why?
| | Healthy Volunteers | 3 | 2018 | 219 | 0.280 |
Why?
| | Endothelin-1 | 2 | 2009 | 181 | 0.280 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 574 | 0.270 |
Why?
| | Energy Intake | 6 | 2020 | 512 | 0.270 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 45 | 0.270 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 49 | 0.270 |
Why?
| | Administration, Oral | 5 | 2015 | 867 | 0.270 |
Why?
| | Kidney | 7 | 2025 | 1497 | 0.270 |
Why?
| | Peroneal Nerve | 5 | 2000 | 18 | 0.270 |
Why?
| | Collagen Type I | 3 | 2014 | 143 | 0.270 |
Why?
| | Upper Extremity | 1 | 2009 | 113 | 0.270 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 544 | 0.270 |
Why?
| | Signal Transduction | 6 | 2014 | 5224 | 0.270 |
Why?
| | Oxygen | 11 | 2022 | 981 | 0.270 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1925 | 0.270 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 290 | 0.270 |
Why?
| | Posture | 6 | 2001 | 197 | 0.270 |
Why?
| | Sports | 5 | 2003 | 212 | 0.270 |
Why?
| | Phosphorylation | 6 | 2013 | 1708 | 0.260 |
Why?
| | Hypercapnia | 2 | 2025 | 53 | 0.260 |
Why?
| | Adiposity | 1 | 2012 | 532 | 0.260 |
Why?
| | Abdomen | 5 | 2004 | 142 | 0.260 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 428 | 0.260 |
Why?
| | Regression Analysis | 10 | 2011 | 1001 | 0.260 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.250 |
Why?
| | Acetophenones | 3 | 2019 | 13 | 0.250 |
Why?
| | Trimethaphan | 5 | 2005 | 6 | 0.250 |
Why?
| | Treatment Outcome | 7 | 2025 | 11794 | 0.250 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 821 | 0.250 |
Why?
| | Swimming | 5 | 2002 | 54 | 0.250 |
Why?
| | Phenylephrine | 5 | 2005 | 74 | 0.250 |
Why?
| | Tunica Media | 3 | 2001 | 37 | 0.250 |
Why?
| | Congresses as Topic | 2 | 2018 | 224 | 0.240 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2601 | 0.240 |
Why?
| | Electrocardiography | 9 | 2005 | 668 | 0.240 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 234 | 0.240 |
Why?
| | Proteins | 3 | 2009 | 1023 | 0.240 |
Why?
| | Pyridinium Compounds | 3 | 2025 | 31 | 0.240 |
Why?
| | Hypoxia | 6 | 1999 | 1199 | 0.240 |
Why?
| | Case-Control Studies | 5 | 2026 | 3634 | 0.230 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 552 | 0.230 |
Why?
| | Sulfonamides | 3 | 2025 | 583 | 0.230 |
Why?
| | Chemokine CXCL12 | 1 | 2026 | 86 | 0.230 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 267 | 0.230 |
Why?
| | Fatty Acids | 2 | 2019 | 457 | 0.230 |
Why?
| | Microcirculation | 2 | 2019 | 142 | 0.230 |
Why?
| | Carbon Dioxide | 3 | 2023 | 227 | 0.230 |
Why?
| | Thermogenesis | 1 | 2005 | 45 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 118 | 0.220 |
Why?
| | Pyruvaldehyde | 1 | 2025 | 46 | 0.220 |
Why?
| | Recovery of Function | 4 | 2017 | 716 | 0.220 |
Why?
| | Brain | 6 | 2023 | 2969 | 0.220 |
Why?
| | Cell Nucleus | 1 | 2008 | 588 | 0.220 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 48 | 0.220 |
Why?
| | Receptors, Adrenergic, alpha | 2 | 2002 | 19 | 0.220 |
Why?
| | MicroRNAs | 1 | 2011 | 686 | 0.220 |
Why?
| | Aged, 80 and over | 14 | 2025 | 8347 | 0.220 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 42 | 0.220 |
Why?
| | Arginine | 1 | 2006 | 264 | 0.220 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 45 | 0.220 |
Why?
| | American Heart Association | 2 | 2020 | 358 | 0.210 |
Why?
| | Mitochondria, Muscle | 1 | 2026 | 120 | 0.210 |
Why?
| | Preventive Medicine | 2 | 2015 | 39 | 0.210 |
Why?
| | Acidosis | 1 | 2025 | 105 | 0.210 |
Why?
| | Veins | 5 | 2009 | 69 | 0.210 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.200 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.200 |
Why?
| | Skin | 4 | 2019 | 754 | 0.200 |
Why?
| | Lactates | 7 | 2007 | 82 | 0.200 |
Why?
| | History, 21st Century | 1 | 2024 | 222 | 0.190 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 79 | 0.190 |
Why?
| | Weight Loss | 2 | 2008 | 859 | 0.190 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 82 | 0.190 |
Why?
| | Blueberry Plants | 1 | 2023 | 8 | 0.190 |
Why?
| | Hand | 8 | 1994 | 157 | 0.190 |
Why?
| | History, 20th Century | 1 | 2024 | 328 | 0.190 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 421 | 0.190 |
Why?
| | Apoptosis | 1 | 2011 | 2444 | 0.190 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 196 | 0.190 |
Why?
| | Cholesterol | 5 | 1997 | 408 | 0.190 |
Why?
| | Myocardium | 5 | 2010 | 935 | 0.180 |
Why?
| | Anthropometry | 3 | 2011 | 206 | 0.180 |
Why?
| | Acetylene | 2 | 2003 | 2 | 0.180 |
Why?
| | Kidney Diseases | 2 | 2025 | 426 | 0.180 |
Why?
| | Authorship | 1 | 2023 | 49 | 0.180 |
Why?
| | Supine Position | 6 | 1999 | 37 | 0.180 |
Why?
| | Fibrinolysis | 2 | 2008 | 164 | 0.180 |
Why?
| | Sugars | 1 | 2022 | 40 | 0.180 |
Why?
| | Respiration | 7 | 1998 | 207 | 0.180 |
Why?
| | Adrenal Medulla | 1 | 2002 | 10 | 0.180 |
Why?
| | Cold Temperature | 7 | 2001 | 206 | 0.180 |
Why?
| | Coronary Disease | 6 | 1998 | 382 | 0.180 |
Why?
| | Citrulline | 1 | 2022 | 45 | 0.180 |
Why?
| | Body Weight | 10 | 2019 | 972 | 0.170 |
Why?
| | Universities | 1 | 2024 | 445 | 0.170 |
Why?
| | Terminology as Topic | 1 | 2023 | 259 | 0.170 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 167 | 0.170 |
Why?
| | Progesterone | 1 | 2002 | 215 | 0.170 |
Why?
| | Sirolimus | 3 | 2021 | 282 | 0.170 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 51 | 0.170 |
Why?
| | Nicotine | 1 | 2023 | 331 | 0.170 |
Why?
| | Fatty Liver | 1 | 2023 | 253 | 0.160 |
Why?
| | Insulin | 11 | 2022 | 2516 | 0.160 |
Why?
| | Weight Gain | 1 | 2004 | 561 | 0.160 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 82 | 0.160 |
Why?
| | Cancer Survivors | 1 | 2026 | 338 | 0.160 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.160 |
Why?
| | Mexican Americans | 1 | 2001 | 119 | 0.160 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 124 | 0.160 |
Why?
| | Knee | 1 | 2000 | 72 | 0.160 |
Why?
| | DNA Methylation | 2 | 2024 | 690 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 171 | 0.150 |
Why?
| | Lipocalin-2 | 1 | 2020 | 80 | 0.150 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 139 | 0.150 |
Why?
| | Triglycerides | 4 | 2017 | 520 | 0.150 |
Why?
| | RNA, Untranslated | 1 | 2021 | 121 | 0.150 |
Why?
| | Lung | 4 | 1999 | 4116 | 0.150 |
Why?
| | Fibrinogen | 2 | 1998 | 180 | 0.150 |
Why?
| | Emotions | 1 | 2025 | 577 | 0.150 |
Why?
| | Functional Food | 1 | 2019 | 4 | 0.150 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 430 | 0.150 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 37 | 0.150 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 28 | 0.150 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 43 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 217 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 365 | 0.150 |
Why?
| | Menopause | 2 | 2006 | 326 | 0.150 |
Why?
| | Rats | 11 | 2015 | 5585 | 0.150 |
Why?
| | Adipokines | 1 | 2019 | 57 | 0.150 |
Why?
| | Sex Factors | 4 | 2025 | 2110 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 474 | 0.140 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 50 | 0.140 |
Why?
| | Social Class | 1 | 2001 | 264 | 0.140 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 765 | 0.140 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 26 | 0.140 |
Why?
| | Linear Models | 2 | 2012 | 849 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2020 | 268 | 0.140 |
Why?
| | Stroke Volume | 7 | 1998 | 655 | 0.140 |
Why?
| | Cohort Studies | 5 | 2013 | 6033 | 0.130 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 361 | 0.130 |
Why?
| | Leptin | 5 | 2019 | 248 | 0.130 |
Why?
| | Methionine | 1 | 2018 | 161 | 0.130 |
Why?
| | Adipocytes | 1 | 2019 | 223 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 132 | 0.130 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 58 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2021 | 401 | 0.130 |
Why?
| | Calcitriol | 1 | 2017 | 58 | 0.130 |
Why?
| | Cardiology | 1 | 2020 | 362 | 0.130 |
Why?
| | Cholecalciferol | 1 | 2017 | 61 | 0.130 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 65 | 0.130 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 31 | 0.120 |
Why?
| | Stress, Psychological | 3 | 1995 | 1151 | 0.120 |
Why?
| | Heart Conduction System | 4 | 2002 | 96 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4568 | 0.120 |
Why?
| | Hyperuricemia | 1 | 2016 | 47 | 0.120 |
Why?
| | Education, Graduate | 1 | 2016 | 35 | 0.120 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 118 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2018 | 1244 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1969 | 0.120 |
Why?
| | Age Distribution | 1 | 1997 | 404 | 0.120 |
Why?
| | Students, Health Occupations | 1 | 2016 | 37 | 0.120 |
Why?
| | Walking | 3 | 2011 | 545 | 0.120 |
Why?
| | Methemoglobin | 1 | 2015 | 24 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1998 | 274 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 318 | 0.120 |
Why?
| | Hemostasis | 2 | 1998 | 98 | 0.110 |
Why?
| | Program Development | 1 | 2018 | 368 | 0.110 |
Why?
| | Myocardial Contraction | 3 | 1988 | 293 | 0.110 |
Why?
| | Risk Assessment | 2 | 2018 | 3752 | 0.110 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 28 | 0.110 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 52 | 0.110 |
Why?
| | Middle Cerebral Artery | 2 | 2025 | 56 | 0.110 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 8 | 0.110 |
Why?
| | Urinalysis | 1 | 2015 | 83 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 529 | 0.110 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 10 | 0.110 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 10 | 0.110 |
Why?
| | Skinfold Thickness | 4 | 1999 | 43 | 0.110 |
Why?
| | Rejuvenation | 1 | 2014 | 18 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 263 | 0.100 |
Why?
| | Rotenone | 1 | 2014 | 20 | 0.100 |
Why?
| | Nutritional Status | 1 | 2016 | 353 | 0.100 |
Why?
| | Mobility Limitation | 1 | 2014 | 67 | 0.100 |
Why?
| | Neurons | 2 | 1995 | 1652 | 0.100 |
Why?
| | Plasma Volume | 3 | 2002 | 20 | 0.100 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 94 | 0.100 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 127 | 0.100 |
Why?
| | Program Evaluation | 1 | 2018 | 944 | 0.100 |
Why?
| | Cell Cycle | 1 | 2016 | 598 | 0.100 |
Why?
| | Liver | 3 | 2017 | 1899 | 0.100 |
Why?
| | Plethysmography | 4 | 2007 | 104 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1547 | 0.100 |
Why?
| | Epidemiology | 1 | 2013 | 32 | 0.100 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 124 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2393 | 0.090 |
Why?
| | Statistics as Topic | 2 | 2011 | 283 | 0.090 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 267 | 0.090 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 74 | 0.090 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 277 | 0.090 |
Why?
| | Administration, Sublingual | 1 | 2012 | 12 | 0.090 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.090 |
Why?
| | Hypotension | 1 | 1993 | 127 | 0.090 |
Why?
| | Body Temperature | 5 | 1991 | 227 | 0.090 |
Why?
| | Catecholamines | 5 | 1996 | 88 | 0.090 |
Why?
| | Mental Processes | 1 | 1992 | 37 | 0.090 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 12 | 0.090 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 116 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 8078 | 0.090 |
Why?
| | Waist Circumference | 1 | 2012 | 143 | 0.090 |
Why?
| | Naphthols | 1 | 2011 | 5 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 138 | 0.090 |
Why?
| | Nitroso Compounds | 1 | 2011 | 7 | 0.090 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 5 | 0.090 |
Why?
| | Metabolism | 2 | 2001 | 44 | 0.080 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 73 | 0.080 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 112 | 0.080 |
Why?
| | Myography | 1 | 2011 | 14 | 0.080 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 18 | 0.080 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 361 | 0.080 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 19 | 0.080 |
Why?
| | Diastole | 3 | 2003 | 146 | 0.080 |
Why?
| | Connective Tissue | 1 | 2010 | 38 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 396 | 0.080 |
Why?
| | Endorphins | 1 | 1990 | 9 | 0.080 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.080 |
Why?
| | Caspases | 1 | 2011 | 233 | 0.080 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 56 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1069 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2022 | 17330 | 0.080 |
Why?
| | Phosphoproteins | 1 | 2012 | 337 | 0.080 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.080 |
Why?
| | Benzamides | 1 | 2011 | 226 | 0.080 |
Why?
| | United States | 3 | 2020 | 16126 | 0.080 |
Why?
| | Fibronectins | 1 | 2010 | 136 | 0.080 |
Why?
| | Phenotype | 2 | 2024 | 3170 | 0.080 |
Why?
| | Communication | 1 | 2016 | 977 | 0.080 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 100 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 250 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5428 | 0.070 |
Why?
| | Diet Records | 1 | 2009 | 89 | 0.070 |
Why?
| | Subclavian Artery | 1 | 1989 | 28 | 0.070 |
Why?
| | Curriculum | 1 | 2016 | 1074 | 0.070 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 27 | 0.070 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 60 | 0.070 |
Why?
| | Leukocyte Count | 1 | 2010 | 318 | 0.070 |
Why?
| | Acclimatization | 1 | 1990 | 170 | 0.070 |
Why?
| | Probability | 1 | 2010 | 308 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 145 | 0.070 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.070 |
Why?
| | Prognosis | 1 | 2018 | 4330 | 0.070 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 3 | 0.070 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.070 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 20 | 0.070 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 29 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2525 | 0.070 |
Why?
| | Homeostasis | 3 | 2021 | 644 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 271 | 0.070 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 78 | 0.070 |
Why?
| | Aortic Coarctation | 1 | 1989 | 78 | 0.070 |
Why?
| | Propranolol | 4 | 2001 | 44 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 860 | 0.070 |
Why?
| | Leukocytes | 1 | 2010 | 296 | 0.070 |
Why?
| | Diet, High-Fat | 2 | 2021 | 266 | 0.070 |
Why?
| | Calorimetry, Indirect | 2 | 2005 | 72 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 408 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 151 | 0.070 |
Why?
| | Interferon-gamma | 1 | 2011 | 784 | 0.070 |
Why?
| | Hyperemia | 1 | 1988 | 49 | 0.060 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 150 | 0.060 |
Why?
| | Catalase | 1 | 2007 | 134 | 0.060 |
Why?
| | Electrophysiology | 3 | 1993 | 218 | 0.060 |
Why?
| | Kinetics | 3 | 1997 | 1568 | 0.060 |
Why?
| | Databases, Factual | 1 | 2013 | 1491 | 0.060 |
Why?
| | Hyperoxia | 2 | 1999 | 107 | 0.060 |
Why?
| | Amidohydrolases | 1 | 2006 | 31 | 0.060 |
Why?
| | Gene Expression | 1 | 2011 | 1478 | 0.060 |
Why?
| | Telomere | 1 | 2010 | 287 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 368 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2933 | 0.060 |
Why?
| | Hormones | 2 | 2002 | 135 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2001 | 252 | 0.060 |
Why?
| | Body Fat Distribution | 1 | 2005 | 46 | 0.060 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 154 | 0.060 |
Why?
| | Hematocrit | 2 | 1997 | 108 | 0.060 |
Why?
| | Arterioles | 1 | 2025 | 52 | 0.060 |
Why?
| | Heart Ventricles | 3 | 2003 | 756 | 0.060 |
Why?
| | Codon | 1 | 2005 | 92 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 48 | 0.060 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 11 | 0.050 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 13 | 0.050 |
Why?
| | Fibroblasts | 1 | 2010 | 1028 | 0.050 |
Why?
| | Vital Capacity | 2 | 2000 | 292 | 0.050 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 6 | 0.050 |
Why?
| | Thigh | 2 | 2003 | 48 | 0.050 |
Why?
| | Vasopressins | 1 | 2005 | 61 | 0.050 |
Why?
| | Calorimetry | 1 | 2004 | 69 | 0.050 |
Why?
| | Imidazoles | 1 | 2025 | 247 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1368 | 0.050 |
Why?
| | Loneliness | 1 | 2025 | 69 | 0.050 |
Why?
| | Up-Regulation | 1 | 2007 | 848 | 0.050 |
Why?
| | Osmolar Concentration | 3 | 2001 | 168 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2514 | 0.050 |
Why?
| | Postprandial Period | 1 | 2004 | 114 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 121 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 630 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2191 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1271 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1507 | 0.050 |
Why?
| | Powders | 1 | 2023 | 44 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2011 | 2805 | 0.050 |
Why?
| | Butanols | 1 | 2022 | 6 | 0.050 |
Why?
| | Hexanols | 1 | 2022 | 7 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1998 | 0.050 |
Why?
| | Femur | 2 | 2001 | 254 | 0.050 |
Why?
| | Biology | 1 | 2023 | 89 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 131 | 0.050 |
Why?
| | Evans Blue | 1 | 2002 | 8 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 106 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 321 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 5 | 0.040 |
Why?
| | Electromyography | 3 | 1989 | 419 | 0.040 |
Why?
| | Phentolamine | 1 | 2001 | 19 | 0.040 |
Why?
| | Mesentery | 1 | 2002 | 44 | 0.040 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2001 | 34 | 0.040 |
Why?
| | Ischemia | 5 | 1994 | 422 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2770 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 544 | 0.040 |
Why?
| | Genotype | 1 | 2007 | 1857 | 0.040 |
Why?
| | Men | 1 | 2001 | 21 | 0.040 |
Why?
| | Lactic Acid | 4 | 1995 | 295 | 0.040 |
Why?
| | Acarbose | 1 | 2021 | 2 | 0.040 |
Why?
| | Models, Biological | 2 | 2004 | 1764 | 0.040 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 24 | 0.040 |
Why?
| | Tidal Volume | 2 | 1993 | 109 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2001 | 19 | 0.040 |
Why?
| | Neurons, Afferent | 2 | 1993 | 102 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 184 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 226 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1062 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 86 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 43 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 128 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2602 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 461 | 0.040 |
Why?
| | Thinness | 1 | 2000 | 100 | 0.040 |
Why?
| | Mexico | 1 | 2001 | 233 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 394 | 0.040 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 72 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 268 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 494 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2123 | 0.040 |
Why?
| | NADP | 1 | 2019 | 52 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 6 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 693 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 1211 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 25 | 0.030 |
Why?
| | Hyperinsulinism | 1 | 2019 | 115 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 521 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2024 | 835 | 0.030 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 15 | 0.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 85 | 0.030 |
Why?
| | Prevalence | 2 | 2005 | 2875 | 0.030 |
Why?
| | Biological Transport | 1 | 2019 | 424 | 0.030 |
Why?
| | Acute Disease | 1 | 2000 | 1036 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 92 | 0.030 |
Why?
| | Mathematics | 2 | 1996 | 101 | 0.030 |
Why?
| | Automation | 1 | 1997 | 104 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 152 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 15 | 0.030 |
Why?
| | Echocardiography | 2 | 2005 | 648 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1327 | 0.030 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 12 | 0.030 |
Why?
| | Cell Respiration | 1 | 2017 | 105 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2016 | 26 | 0.030 |
Why?
| | Weight Lifting | 3 | 1988 | 31 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 112 | 0.030 |
Why?
| | Myoblasts | 1 | 2017 | 83 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 211 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 203 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 248 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 209 | 0.030 |
Why?
| | Pain | 2 | 1992 | 791 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 201 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 12 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 52 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1559 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 40 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 25 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2968 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 312 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 150 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 58 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 26 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 84 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 199 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 302 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 61 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 6 | 0.030 |
Why?
| | Health | 1 | 2014 | 82 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 314 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 241 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3418 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 19 | 0.020 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 28 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 534 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 730 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2015 | 311 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 858 | 0.020 |
Why?
| | Educational Measurement | 1 | 2016 | 326 | 0.020 |
Why?
| | Reflex, Stretch | 1 | 1993 | 11 | 0.020 |
Why?
| | Denervation | 1 | 1993 | 27 | 0.020 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 13 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 456 | 0.020 |
Why?
| | Venous Pressure | 1 | 1992 | 6 | 0.020 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 50 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2013 | 77 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 1995 | 292 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 557 | 0.020 |
Why?
| | Fingers | 1 | 2013 | 107 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1993 | 335 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 630 | 0.020 |
Why?
| | Skin Temperature | 1 | 1992 | 36 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 166 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2823 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 9 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 264 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 198 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 75 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 3 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 329 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 21 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 157 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 2 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 461 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 762 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 79 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 166 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 29 | 0.020 |
Why?
| | Fever | 1 | 1990 | 320 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 145 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 351 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 12 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 178 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 27 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 40 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 6 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1049 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 374 | 0.020 |
Why?
| | Child | 3 | 1997 | 22740 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 197 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 450 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 618 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1166 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 411 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 41 | 0.010 |
Why?
| | Environmental Exposure | 1 | 1991 | 578 | 0.010 |
Why?
| | Fatigue | 1 | 1988 | 366 | 0.010 |
Why?
| | Blood Proteins | 1 | 1988 | 239 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1990 | 697 | 0.010 |
Why?
| | Syncope | 1 | 1986 | 56 | 0.010 |
Why?
| | Feedback | 1 | 2005 | 180 | 0.010 |
Why?
| | Anabolic Agents | 1 | 1984 | 13 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 64 | 0.010 |
Why?
| | Dogs | 1 | 2005 | 478 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1752 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1984 | 99 | 0.010 |
Why?
| | Affect | 1 | 2007 | 321 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3130 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 356 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 190 | 0.010 |
Why?
| | Methods | 1 | 1983 | 68 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 11 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 181 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 164 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 3 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 602 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 20 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 411 | 0.010 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2001 | 57 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 138 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 19 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 18 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 42 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 196 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 484 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 115 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 35 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 254 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 59 | 0.000 |
Why?
| | Pain Measurement | 1 | 1992 | 562 | 0.000 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.000 |
Why?
| | Growth Hormone | 1 | 1988 | 91 | 0.000 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.000 |
Why?
| | Glycerol | 1 | 1988 | 90 | 0.000 |
Why?
| | Thyroid Hormones | 1 | 1988 | 69 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 154 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 317 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 9 | 0.000 |
Why?
| | Risk | 1 | 1987 | 923 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 117 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 61 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 502 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 416 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 1103 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|